These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7905550)

  • 1. Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
    Goldhirsch A; Gelber RD; Price KN; Castiglione M; Coates AS; Rudenstam CM; Collins J; Lindtner J; Hacking A; Marini G
    Lancet; 1994 Feb; 343(8894):377-81. PubMed ID: 7905550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.
    Castiglione-Gertsch M; Tattersall M; Hacking A; Goldhirsch A; Gudgeon A; Gelber RD; Lindtner J; Coates A; Collins J; Isley M; Senn HJ; Rudenstam CM
    Eur J Cancer; 1997 Dec; 33(14):2321-5. PubMed ID: 9616275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
    Levine MN; Bramwell V; Abu-Zahra H; Goodyear MD; Arnold A; Findlay B; Skillings J; Gent M
    Br J Cancer; 1992 Jan; 65(1):130-2. PubMed ID: 1733435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
    J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses.
    Goldhirsch A; Gelber RD; Castiglione M
    J Clin Oncol; 1988 Jan; 6(1):89-97. PubMed ID: 3275752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
    Aebi S; Gelber S; Castiglione-Gertsch M; Gelber RD; Collins J; Thürlimann B; Rudenstam CM; Lindtner J; Crivellari D; Cortes-Funes H; Simoncini E; Werner ID; Coates AS; Goldhirsch A
    Lancet; 2000 May; 355(9218):1869-74. PubMed ID: 10866443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
    Ludwig Breast Cancer Study Group
    Lancet; 1984 Jun; 1(8389):1256-60. PubMed ID: 6144974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
    Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
    J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
    Forrest AP; Stewart HJ; Everington D; Prescott RJ; McArdle CS; Harnett AN; Smith DC; George WD
    Lancet; 1996 Sep; 348(9029):708-13. PubMed ID: 8806289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
    Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
    NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
    Falkson HC; Gray R; Wolberg WH; Gillchrist KW; Harris JE; Tormey DC; Falkson G
    J Clin Oncol; 1990 Apr; 8(4):599-607. PubMed ID: 2179477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.